Contact us today to begin your journey toward safe, healthy, and lasting weight loss.
Weight loss may slow : A slower rate is not failure
The RAAS in the Pathogenesis and Treatment of Diabetic Nephropathy
Your doctor can: Review your medication history for other drugs that may affect libido (such as antidepressants, antihypertensives, or hormonal treatments) Assess for underlying conditions (thyroid disorders, diabetes complications, cardiovascular disease, depression, or anxiety) Arrange appropriate investigations, which may include blood tests for hormones and metabolic parameters
Research findings reveal substantially elevated gastrointestinal risks demonstrating: Pancreatitis Risk : Patients using GLP-1 agonists showed a 9.09-fold increased risk (adjusted hazard ratio) for developing pancreatitis compared to those using alternative weight loss medications Gastroparesis Development : The study revealed a 3.67-fold increased risk for gastroparesis, often occurring secondary to pancreatic inflammation Bowel Obstruction : A 4.22-fold increased risk for intestinal blockages was documented, frequently accompanying severe gastroparesis cases FDA Adverse Event Reports : Analysis of the FDAs FAERS database through 2024 shows over 900 reported cases of pancreatitis specifically linked to semaglutide use Post-Marketing Surveillance : Real-world data from 2023-2024 indicates that serious gastrointestinal events occur more frequently than initially reported in clinical trials When pancreatitis develops, the inflamed pancreas releases numerous enzymes, toxic substances, and vasoactive compounds including inflammatory cytokines that can damage the autonomic nervous system controlling gastric function
Semaglutide products include Ozempic, Rybelsus, Wegovy, and Wegovy HD, while tirzepatide products include Mounjaro and Zepbound
